Mylan N.V. (Nasdaq: MYL) today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep™ in India. The product is indicated for the treatment of chronic hepatitis C, a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.
In September 2014, Mylan entered into a licensing and technology transfer agreement with Gilead granting Mylan the non-exclusive rights to manufacture and distribute generic Sofosbuvir in 91 developing countries, including India.
Mylan President Rajiv Malik said, "The launch of Mylan's MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option. We look forward to bringing that same hope to millions of more hepatitis C patients as we expand access to MyHep in the developing world."
MyHep is an important addition to Mylan's growing commercial business in India and is sold by Mylan's dedicated sales force as part of its Hepato Care segment. The company also offers four additional unique and innovative segments – Critical Care, HIV Care, Women's Care and Oncology.
How gut microbiome and fiber diversity shape chronic disease outcomes